Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

C023 - Dermatology Review: General Dermatology and Practice Management

Sunday, February 18; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize new developments in general dermatology.
  • Analyze and describe best practices for practice management, coding, and electronic health records.
  • Evaluate new treatment options for dermatologic conditions, including acne, rosacea, psoriasis, and eczema.

Description

This course will comprehensively review new developments in medical, cosmetic and surgical dermatology. Innovation in diagnosis and treatment of common dermatologic conditions, such as skin cancer, actinic keratosis, psoriasis, eczema, acne, contact dermatitis, infectious diseases in dermatology, and rosacea will be reviewed. New developments in cosmetic dermatology and best practices in surgical and cosmetic dermatology will be reviewed. Practice management, including billing, coding, electronic health records, and new payment models.

Disclosures

  • Berman, Brian, MD, PhD: Aclaris Therapeutics, Inc. – A(H), C(H); Actavis – I(Grants/Research Funding); AiViva BioPharma, Inc. – C(H); Allergan, Inc. – I(Grants/Research Funding); Allos – A(H); Almirall – A(H); Amira Pharmaceuticals – C(H); Anacor Pharmaceuticals, Inc. – A(H), I(Grants/Research Funding); Bayer Pharmaceuticals – SP(H); Berg Pharma, LLC – A(ST), C(H); Biofrontera AG – C(H); C & H Scientific, LLC – A(H); Capstone Therapeutics Corp. – C(H); Celumigen Pharmaceuticals, Inc. – B(SO), C(H), C(SO); Centocor Ortho Biotech Inc. – C(H), SP(H); CHS Pharma – A(ST); Clark Pharmaceuticals, LLC – C(H); Crescita Therapeutics Inc. – C(H); Dermira – A(H), A(SO); Doak – A(H); Dr. Tattoff – A(H), A(SO); DUSA Pharmaceuticals, Inc – A(H); DUSA Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding); Excaliard Pharmaceuticals, Inc. – C(H); Exeltis – C(H), I(Grants/Research Funding); Ferndale Laboratories, Inc. – C(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – C(H); Graceway Pharmaceuticals, LLC – SP(H); Halscion – A(H); Klara/Goderma, Inc. – C(SO); Leo Pharma A/S – I(Grants/Research Funding); LEO Pharma, US – A(H), SP(H); Liquidia Technologies, Inc. – C(H); Medicis Pharmaceutical Corporation – A(H), SP(H); Medimetriks Pharmaceuticals, Inc. – C(H); MediWound – C(H); Menlo Therapeutics – A(H); Merz Pharmaceuticals, LLC – A(H), Speaker/Faculty Education(H); Novan – C(H); Novartis Pharmaceuticals Corp. – SP(H); Oculus innovative Sciences, Inc. – C(SO); Onset Therapeutics – A(H), SP(H); Peplin Inc. – A(H), C(H); Pharmaderm – A(H); Pulse Biosciences – C(H); Realm Therapeutics – C(H); RXi Pharmaceuticals Corporation – I(NC); sanofi-aventis – A(H), SP(H); Seattle Genetics – A(H); Sensus Healthcare – A(H); Sirnaomics, Inc. – C(H); Smith & Nephew – A(H); Sol-Gel Technologies – C(H); Stiefel a GSK company – A(H), SP(H); Tigercat Pharma, Inc – I(Grants/Research Funding); TopMD – A(ST), C(H); Valeant Pharmaceuticals International – SP(H);
  • Goldenberg, Gary, MD: AbbVie – SP(H); Allergan, Inc – C(H); Anacor Pharmaceuticals, Inc. – C(H); Bayer – SP(H); Bayer Pharmaceuticals – C(H); Castle Biosciences – SP(H); Celgene Corporation – C(H), SP(H); Dermira – A(H); Eclipse Medical – C(H); Eli Lilly and Company – C(Fees), SP(H); Galderma USA – SP(H); Genentech, Inc. – C(H); Janssen Pharmaceuticals, Inc – C(H); Leo Pharma A/S – I(Grants/Research Funding); LEO Pharma, US – C(H), SP(H); MelaSciences – C(H); Novartis Pharmaceuticals Corp. – C(H), SP(H); Pfizer Inc. – C(H); Pharmaderm – A(H), I(Grants/Research Funding), SP(H); Ranbaxy Laboratories Limited – C(H); Stiefel a GSK company – C(H), I(Grants/Research Funding); Taro Pharm – C(Fees); Teva Pharmaceuticals USA – C(Fees); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding), SP(H); Xoft – C(H);
  • Green, Lawrence J., MD: Abbott Laboratories – SP(H); Allergan, Inc. – C(H), I(Grants/Research Funding), Speaker/Faculty Education(H); Amgen – I(Grants/Research Funding), SP(H); Brickell Biotech, Inc. – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding), SP(H); Dermira – I(Grants/Research Funding); ISDIN – C(H); Leo Pharma Inc. – SP(H); LEO Pharma, US – I(Grants/Research Funding); Merz Aesthetics – A(H), I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding), SP(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding);
  • Kaufmann, Mark D., MD: Aclaris Therapeutics, Inc. – C(Fees); Almirall – C(Fees); Castle Biosciences, Inc – C(Fees); Dermira – C(Fees); Encore Dermatology, Inc. – C(Fees); Exeltis – C(Fees); Galderma Laboratories, L.P. – C(Fees); IntraDerm Pharmaceuticals – C(Fees); JBT Dermatology – C(Fees); Klara/Goderma, Inc. – C(SO); L'Oreal USA Inc. – C(Fees); La Roche-Posay Laboratorie Pharmaceutique – C(Fees); Menlo Therapeutics – C(Fees); Modernizing Medicine – C(SO); Ortho Dermatologics – C(Fees); Pfizer Inc. – C(Fees); Promius Pharma, LLC – C(Fees); Sensus Healthcare – C(Fees); Suneva Medical, Inc. – C(Fees);
  • Kircik, Leon H., MD: 3M Pharmaceuticals – I(Grants/Research Funding), SP(H); Abbott Laboratories – SP(H); Ablynx – I(Grants/Research Funding); Acambis – I(Grants/Research Funding); Allergan, Inc – A(H), C(H), I(H), SP(H); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding), SP(H); Astellas Pharma US, Inc – I(Grants/Research Funding), SP(H); Asubio Pharmaceuticals, Inc. – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Biogen – A(H); Biolife – I(Grants/Research Funding); Biopelle, Inc. – I(Grants/Research Funding); Breckinridge Pharma – I(Grants/Research Funding); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); ColBar LifeScience Ltd. – A(H), C(H); CollaGenex Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding), SP(H); Connetics Corporation – A(H), C(H), I(Grants/Research Funding); Coria Laboratories – I(Grants/Research Funding); Dermik Laboratories, a business of sanofi-aventis U.S. LLC – SP(H); Dow Pharmaceutical Sciences, Inc. – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Embil Pharmaceuticals, Co., Ltd – SP(H); EOS – A(H); Ferndale Laboratories, Inc. – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – A(H), C(H), I(Grants/Research Funding); Isdin – A(H); Johnson & Johnson Consumer Products Company – A(H), C(H), I(Grants/Research Funding), SH(ST), SP(H); Laboratory Skin Care, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding), SP(H); Medical International Technologies – C(H); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc – C(H); Merck Serono – SP(H); Merz Pharmaceuticals, LLC – C(H); NanoBio Corporation – A(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Nucryst – I(Grants/Research Funding); Obagi Medical Products – I(Grants/Research Funding); Onset Dermatologics – I(Grants/Research Funding), SP(H); Othro Dermatologics – A(H), C(H), I(Grants/Research Funding), SP(H); Pfizer Inc. – I(Grants/Research Funding); Pharmaderm – I(Grants/Research Funding), SP(H); Promius Pharma, LLC – A(H), C(H), I(Grants/Research Funding); PuraCap Pharmaceutical – C(H); QLT Inc. – I(H); SkinMedica, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); Stiefel a GSK company – A(H), C(H), I(Grants/Research Funding), SP(H); Sun Pharmaceutical Industries Ltd. – A(H); TolerRx – I(Grants/Research Funding); Triax Pharmaceuticals, LLC – C(H), I(Grants/Research Funding), SP(H); Valeant Pharmaceuticals International – A(H), C(H), I(Grants/Research Funding), SP(H); Warner Chilcott – A(H), I(Grants/Research Funding), SP(H); Xenoport, Inc. – I(Grants/Research Funding); Zalicus – I(Grants/Research Funding);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Aqua – C(H); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Corrona, Inc. – O(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); Medimmune – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Vidac Pharma – I(Grants/Research Funding);
  • Lober, Clifford Warren, MD, JD: no financial relationships exist with commercial interests.
  • Rosen, Theodore, MD: Medimetriks Pharmaceuticals, Inc. – C(H); Menlo Therapeutics – A(H); Valeant Pharmaceuticals International – C(H);
  • Siegel, Daniel M., MD, MS: Actavis – I(Grants/Research Funding); Allergan, Inc – A(H); Athenex – A(H); Biofrontera AG – A(H), SH(ST); Caliber Imaging and Diagnostics Inc. – B(SO); Castle Biosciences, Inc – A(H); Clearpath Solutions Group – A(H); Dantech Systems – F(IP); DermTech International – A(SO); Elsevier Inc. – O(IP); Ferndale Laboratories, Inc. – A(H); Fiorello Pharmaceuticals, Inc. – B(NC), SH(NC); Galderma Laboratories, L.P. – A(H); Genentech, Inc. – SP(H); Gerson Lehrman Group – C(Fees); Kamedis Limited – A(Fees), C(ST); Klara/Goderma, Inc. – A(SO); Leerink Swann – C(H); LEO Pharma, US – A(H), C(H); Logical Images – C(SO); Menlo Therapeutics – A(H); Modernizing Medicine – A(SO); Novascan – SH(NC); Or-Genix, Therapeutics – B(SO); Pfizer Inc. – A(H); Photomedex – A(ST); RaMedical – SH(NC); Regeneron – I(Grants/Research Funding); Sanova Works – O(H); Sensus Healthcare – C(Fees); SkinVision – A(SO); Sun Pharmaceutical Industries Ltd. – A(H); Tetros Group – A(NC); Valeant Pharmaceuticals International – C(Fees); Valeant Pharmaceuticals North America LLC – A(H); Vivacare – A(NC); Xoft – C(Fees);
  • Stein Gold, Linda F., MD: AbbVie – A(H); Actavis – SP(H); Allergan, Inc – A(H); Allergan, Inc. – I(Grants/Research Funding); Aqua – A(H); Ferndale Laboratories, Inc. – C(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); La Roche-Posay Laboratorie Pharmaceutique – A(H); Leo Pharma Inc. – I(Grants/Research Funding); LEO Pharma, US – A(H); Lilly ICOS LLC – A(H); Medicis Pharmaceutical Corporation – A(H); Merz Pharmaceuticals, LLC – A(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); Promius Pharmaceuticals – A(H); Roche Laboratories – Independent Contractor(Fees), O(H); Stiefel a GSK company – A(H), I(Grants/Research Funding); Taro Pharm – A(H); Topica – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), I(Grants/Research Funding);
  • Tomecki, Kenneth J., MD: no financial relationships exist with commercial interests.
Schedule
Sunday, February 18
1:00 PM
Dr. Lober / Update on MACRA, MIPS, and APMs
1:15 PM
Dr. Kaufmann / Update on Electronic Health Records
1:30 PM
Dr. Tomecki / Vaccines in dermatology
1:45 PM
Dr. Berman / Control of Post-Surgical Scarring and Keloids
2:00 PM
Dr. Stein Gold / Treatment of acne in 2018
2:15 PM
Dr. Lober, Dr. Tomecki, Dr. Berman, Dr. Stein Gold, and Dr. Kaufmann / Q&A
2:30 PM
Dr. Green / Rosacea update
2:45 PM
Dr. Siegel / ICD-10 Update
3:00 PM
Dr. Lebwohl / Treatment pearls for psoriasis and eczema
3:15 PM
Dr. Kircik / How to correct your common coding mistakes
3:30 PM
Dr. Rosen / STD's in 2018 - What's New
3:45 PM
Dr. Siegel, Dr. Rosen, Dr. Lebwohl, Dr. Kircik, and Dr. Green / Q&A
Event Details
  • Date
    Sunday, February 18
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 8
  • CME Credits
    3.00
  • Type
    Ticketed
    Practice Management
Directors/Co-Directors
  • Gary Goldenberg, MD, FAAD
Speakers
  • Brian Berman, MD, PhD, FAAD
  • Clifford Warren Lober, MD, JD, FAAD - Handout
  • Daniel M. Siegel, MD, MS, FAAD - Handout
  • Kenneth J. Tomecki, MD, FAAD
  • Lawrence J. Green, MD, FAAD - Handout
  • Leon H. Kircik, MD, FAAD - Handout 1, Handout 2, Handout 3
  • Linda F. Stein Gold, MD, FAAD
  • Mark D. Kaufmann, MD, FAAD - Handout
  • Mark Lebwohl, MD, FAAD - Handout
  • Theodore Rosen, MD, FAAD - Handout